DUBLIN – Even if much of the focus of the inaugural Biopharma Ambition meeting here was, as the name suggests, on how Ireland can compete to win more investment from the global biopharma industry, scheduling Sir Andrew Dillon, CEO of England's National Institute for Health and Care Excellence (NICE), as the final speaker in the final plenary session, suggested a certain amount of realism on the part of the conference organizers.